Recent publications by Researchers affiliated with the Centre for Tropical Medicine and Global Health
Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET Cohort
Hassan S. et al, (2024), Blood Advances
Predictive parameters for spontaneous joint bleeding during emicizumab prophylaxis
Arcudi S. et al, (2024), Blood Advances
Prognostic prediction models for clinical outcomes in patients diagnosed with visceral leishmaniasis: protocol for a systematic review.
Wilson J. et al, (2023), BMJ open, 13
EFFECT OF DNA METHYLATION ON INHIBITOR DEVELOPMENT IN HEMOPHILIA A PATIENTS TREATED WITH FVIII CONCENTRATES
Chand H. et al, (2023), HAEMOPHILIA, 29, 27 - 27
FVIII-SPECIFIC IGA ANTIBODIES AND HISTORY OF HEPATITIS C VIRUS INFECTION: A CROSS-SECTIONAL NATIONWIDE STUDY IN PERSONS WITH HEMOPHILIA A
Oomen I. et al, (2023), HAEMOPHILIA, 29, 25 - 25
Development and validation of an early warning model for hospitalized COVID-19 patients: a multi-center retrospective cohort study
Smit JM. et al, (2022), Intensive Care Medicine Experimental, 10
External validation of risk scores to predict in-hospital mortality in patients hospitalized due to coronavirus disease 2019
Hassan S. et al, (2022), European Journal of Internal Medicine, 102, 63 - 71
Socioeconomic participation of persons with hemophilia: Results from the sixth hemophilia in the Netherlands study
van Balen EC. et al, (2022), Research and Practice in Thrombosis and Haemostasis, 6, e12741 - e12741
The usefulness of D-dimer as a predictive marker for mortality in patients with COVID-19 hospitalized during the first wave in Italy
Hassan S. et al, (2022), PLOS ONE, 17, e0264106 - e0264106
Genetic variants at the chromosomal region 2q21.3 underlying inhibitor development in patients with severe haemophilia A
Spena S. et al, (2022), Haemophilia, 28, 270 - 277
Hepatitis C virus in hemophilia: Health‐related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study
Isfordink CJ. et al, (2021), Research and Practice in Thrombosis and Haemostasis, 5, e12616 - e12616
Validation of PROMIS Profile‐29 in adults with hemophilia in the Netherlands
van Balen EC. et al, (2021), Journal of Thrombosis and Haemostasis, 19, 2687 - 2701
Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972–2019
Hassan S. et al, (2021), Journal of Thrombosis and Haemostasis, 19, 2394 - 2406
Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study
Versloot O. et al, (2021), Haemophilia, 27, 876 - 885
Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A
Hassan S. et al, (2021), Haemophilia, 27
Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001–2018
Hassan S. et al, (2021), Journal of Thrombosis and Haemostasis, 19, 645 - 653
Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia A— A Systematic Review and Meta-Analysis
Abdi A. et al, (2020), Frontiers in Immunology, 11
Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?
Hassan S. et al, (2018), Seminars in Thrombosis and Hemostasis, 44, 531 - 543
Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review
Hassan S. et al, (2018), Journal of Thrombosis and Haemostasis, 16, 1055 - 1068